Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

bioAffinity Technologies (BIAF) Non-cash Items (2022 - 2024)

bioAffinity Technologies (BIAF) has disclosed Non-cash Items for 3 consecutive years, with $243097.0 as the latest value for Q1 2024.

  • On a quarterly basis, Non-cash Items fell 10.39% to $243097.0 in Q1 2024 year-over-year; TTM through Mar 2024 was $243097.0, a 10.39% decrease, with the full-year FY2023 number at $158332.0, down 3.61% from a year prior.
  • Non-cash Items was $243097.0 for Q1 2024 at bioAffinity Technologies, up from $158332.0 in the prior quarter.
  • In the past five years, Non-cash Items ranged from a high of $647793.0 in Q3 2022 to a low of $158332.0 in Q4 2023.
  • A 3-year average of $287185.4 and a median of $254225.0 in 2023 define the central range for Non-cash Items.
  • Biggest YoY gain for Non-cash Items was 3.61% in 2023; the steepest drop was 60.76% in 2023.
  • bioAffinity Technologies' Non-cash Items stood at $164255.0 in 2022, then fell by 3.61% to $158332.0 in 2023, then skyrocketed by 53.54% to $243097.0 in 2024.
  • Per Business Quant, the three most recent readings for BIAF's Non-cash Items are $243097.0 (Q1 2024), $158332.0 (Q4 2023), and $254225.0 (Q3 2023).